Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Str8Shuteron Dec 05, 2020 10:20am
124 Views
Post# 32043659

RE:RE:RE:RE:RE:Any idea why the new warrants are priced

RE:RE:RE:RE:RE:Any idea why the new warrants are priced Neither WS nor WT are partial warrants.  They are both full warrants.  You can't trade in half-warrants.  The half warrants were just the incentive for the investors who participated in the most recent public offering.  Each full DEC/23 warrant (i.e. two half warrants) is tradable as SZLS.WS.

There is no conversion factor for the WS warrants as there is for WT.  A single WS warrant allows the holder to buy a single common share of SZLS, whereas you will need 8 WT to buy a single common share when the warrants are exercised.  So, InvrsContrarian's math and analysis was mostly correct.  GLTA


davewho wrote: sorry I see the szls.ws closed at 16 cents according to TD. So if each is a half warrant. It would be 16+16+1.10 = 1.42 to be in the money if you are planning to hold them. Trading them is completely different strategy. 


<< Previous
Bullboard Posts
Next >>